Patents Assigned to Array Biopharma Inc.
  • NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20120208995
    Abstract: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: April 19, 2012
    Publication date: August 16, 2012
    Applicants: Array BioPharma, Inc., InterMune, Inc.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Steven W. Andrews, Pierre Martin, Andreas Schumacher, Bradley Barnett, C. Todd Eary, Robert Kaus, Timothy Kercher, Weidong Liu, Michael Lyon, Paul Nichols, Bin Wang, Tarek Sammakia, April Kennedy, Yutong Jiang
  • Mitotic kinesin inhibitors and methods of use thereof
    Patent number: 8236825
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: August 7, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen R Laird, John Robinson, Shelley Allen
  • Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
    Patent number: 8212045
    Abstract: Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: July 3, 2012
    Assignee: Array BioPharma, Inc.
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Indrani W. Gunawardana, Ronald Jay Hinklin, Ajay Singh, Timothy M. Turner, Eli M. Wallace
  • Heterocyclic inhibitors of MEK and methods of use
    Patent number: 8211921
    Abstract: Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, W, and X are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: July 3, 2012
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Joseph P. Lyssikatos, Allison L. Marlow, Jeongbeob Seo, Eli M. Wallace, Hong-Woon Yang
  • 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof
    Patent number: 8211920
    Abstract: Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases and inflammatory conditions in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: July 3, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Pyrazole urea derivatives used as kinase inhibitors
    Patent number: 8202899
    Abstract: Compounds of Formula (I) where R1 and R2 are as defined herein, and pharmaceutically acceptable salts thereof, are useful in the treatment and prevention of various disorders mediated by kinases.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: June 19, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Mark C. Munson, Brian C. Baer
  • Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
    Patent number: 8193230
    Abstract: Disclosed are pharmaceutical compositions comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of using such compositions for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: June 5, 2012
    Assignee: Array Biopharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent number: 8193229
    Abstract: Disclosed are methods of treating a hyperproliferative disorder or a disease related to vasculogenesis or angiogenesis in a mammal, comprising administering to said mammal an effective amount of a compound of the formula or a pharmaceutically accepted salt thereof, wherein A, R1, R2, R7, R8, and R9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: June 5, 2012
    Assignee: Array Biopharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
    Patent number: 8193231
    Abstract: Disclosed are pharmaceutical compositions comprising 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of using such compositions for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: June 5, 2012
    Assignee: Array Biopharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • 4-substituted phenoxyphenylacetic acid derivatives
    Patent number: 8183289
    Abstract: Compounds of Formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: May 22, 2012
    Assignee: Array BioPharma Inc.
    Inventors: George Doherty, Adam Cook
  • SNAR process for preparing benzimidazole compounds
    Patent number: 8183385
    Abstract: Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-2 and their synthetic intermediates: wherein X1, X2, X5, R1, R2 and R4 are as defined herein. Compounds of Formula Ia-2 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: May 22, 2012
    Assignees: Array BioPharma Inc., AstraZeneca AB
    Inventors: John DeMattei, Sagar Shakya, Paul J. Nichols, Bradley R. Barnett, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, John Leonard
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent number: 8178693
    Abstract: Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein A, R1, R2, R7, R8, and R9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: May 15, 2012
    Assignee: Array Biopharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Pyrrolopyridines as kinase inhibitors
    Patent number: 8178131
    Abstract: Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: May 15, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Yvan Le Huerou, James F. Blake, Indrani W. Gunawardana, Peter J. Mohr, Eli M. Wallace, Bin Wang, Mark Joseph Chicarelli, Michael Lyon
  • Aminodiazepines as toll-like receptor modulators
    Patent number: 8163738
    Abstract: Provided are compositions and methods useful for modulation signaling through the Toll-like receptor TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: April 24, 2012
    Assignee: Array BioPharma Inc.
    Inventors: George A. Doherty, Zachary Jones
  • 8-substituted benzoazepines as toll-like receptor modulators
    Patent number: 8153622
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: April 10, 2012
    Assignee: Array BioPharma Inc.
    Inventors: George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
    Patent number: 8138181
    Abstract: Compounds of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: March 20, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Julie Marie Greschuk, Nicholas C. Kallan, Fredrik P. Marmsäter, Mark C. Munson, James P. Rizzi, John E. Robinson, Stephen T. Schlachter, George T. Topalov, Qian Zhao, Joseph P. Lyssikatos
  • 6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof
    Patent number: 8101639
    Abstract: Disclosed are compounds of the Formulas I and V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: January 24, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong-Woon Yang, James Blake
  • Substituted pyridazines inhibitors of MEK
    Patent number: 8101611
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: January 24, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong woon Yang, James F. Blake
  • Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
    Patent number: 8088766
    Abstract: Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Methods of treating hyperproliferative diseases in mammals are also disclosed.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: January 3, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topolov, Qian Zhao, Joseph P. Lyssikatos
  • Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
    Patent number: 8063050
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: November 22, 2011
    Assignees: Array BioPharma Inc., Covenentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Banka, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do